Use of moxonidine for postmyocardial infarction treatment
View Patent ↗A method of treating myocardial damage secondary to myocardial infarction using moxonidine or a physiologically compatible salt thereof. Pharmaceutical preparations containing moxonidine and its physiologically compatible acid addition salts are suitable for use in acute myocardial infarction and/or postmyocardial infarction management. In addition to a beneficial influence, promoting recovery and/or rehabilitation, on the myocardial status following myocardial infarction, moxonidine and its physiologically compatible acid addition salts, especially when used in the management of postmyocardial infarction patients in the chronic stage, also show a preventive effect against the progression of heart failure after myocardial infarction.
1. A method of treating myocardial damage secondary to myocardial infarction in a patient who has suffered a myocardial infarction, said method comprising administering to said patient who has suffered the myocardial infarction an amount of 4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methylpyrimidine corresponding to formula I:
or a physiologically compatible salt thereof effective to inhibit myocardial damage secondary to myocardial infarction.
2. A method according to claim 1 , wherein the compound of Formula I or physiologically compatible salt thereof is administered for treating myocardial damage secondary to myocardial infarction in acute myocardial infarction.
3. A method according to claim 1 , wherein the compound of Formula I or physiologically compatible salt thereof is administered for postmyocardial infarction management.
4. A method according to claim 3 , wherein the compound of Formula I or physiologically compatible salt thereof is administered for treating myocardial damage secondary to myocardial infarction in the management of chronic postmyocardial infarction patients.
5. A method according to claim 1 , for treating myocardial damage secondary to myocardial infarction, wherein an amount of the compound of Formula I or physiologically compatible salt thereof that is effective in promoting recovery or rehabilitation of myocardial status is administered in admixture with at least one pharmaceutical adjuvant or carrier.